Connect with us

Technology

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results

Published

1 year ago

on

$251 million of Total revenue in 2023

$139 million in Cell Engineering services revenue, representing 31% growth over 2022

78 new Cell Programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma

Year-end cash balance of nearly $950 million provides meaningful multi-year runway as we drive towards profitability and begin recognizing benefits from improved platform efficiency

BOSTON, Feb. 29, 2024 /PRNewswire/ — Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023. The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.

“2023 was a breakout year for Ginkgo,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’re working to build a durable platform that fundamentally transforms R&D in biotech. I’m particularly pleased with our growth in biopharma, which represents our largest untapped market – we added several new programs across modalities with large enterprises including Boehringer Ingelheim, Merck, Novo Nordisk, and Pfizer and are seeing strong momentum in pharma going into 2024. I am also thrilled to see a real ecosystem building around Ginkgo – we’re honored by the trust placed in us by the terrific founders of Patch Biosciences, Reverie Labs, and Proof Diagnostics to bring their technologies to customers and by the over 25 inaugural partners in our newly announced Technology Network. We are committed to bringing the best technologies together to support our customers, and we’ve never been better positioned to deliver.”

Recent Business Highlights & Strategic Positioning

Added 78 new Cell Engineering Programs in 2023, representing 32% growth over the prior year periodGinkgo’s Cell Engineering segment generated services revenue, which does not include downstream value share revenue, of $139 million in 2023, a 31% increase versus 2022Ginkgo’s Biosecurity segment generated $108 million of revenue in 2023 as the Biosecurity business shifted to a more recurring model focused on global reach and multiple pathogens to build a long-term biosecurity global infrastructureGinkgo continues to expand its global bioradar network—now in 14 countries and 10 airports—and advance capabilities for multi-target and multimodal biological threat detection, characterization, and forecasting for next-generation biological intelligenceGinkgo is partnering with the Qatar Free Zones Authority (QFZ) and Doha Venture Capital (DVC) to build a Center for Unified Biosecurity Excellence in Doha (CUBE-D), envisioned as the first of several hubs for biosecurity sample and data analysis in our global networkGinkgo is partnering with Illumina, a global leader in DNA sequencing and array-based technologies, to advance localized biosecurity capabilities in countries around the worldDownstream value share – which consists of potential value to Ginkgo from its Cell Engineering customers and includes potential royalties, milestone payments, and equity interests – is an important component of the financial potential of most programs. As of December 31, 2023 Ginkgo has approximately $2.4 billion in aggregate revenue potential from downstream milestone payments alone in addition to royalties.Ginkgo recently announced the launch of its Technology Network of over 25 companies, creating a more integrated approach to biotech R&D. Ginkgo has a long history of integrating diverse technologies to deliver on customers’ complex program goals and believes that customers should not have to choose a technical approach prematurely but should be able to test many approaches in an unbiased way. Ginkgo customers will be able to benefit from the integration of technologies from network partners in their programs, and Ginkgo expects to expand the network based on customer needs and feedback.Ginkgo also announced several acquisitions including Patch Biosciences, Proof Diagnostics and Reverie Labs. These acquisitions are expected to expand Ginkgo’s capabilities in AI and biopharma.

Fourth Quarter 2023 Financial Highlights

Fourth quarter 2023 Total revenue of $35 million, down from $98 million in the comparable prior year period, a decrease of 65% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment and the impact of Cell Engineering downstream value share from equity milestones in 2022 that did not recur in 2023Fourth quarter 2023 Cell Engineering services revenue, which does not include downstream value share revenue, of $27 million, down 26% from $36 million in the comparable prior year period. There was no material downstream value share revenue received in the fourth quarter of 2023.Fourth quarter 2023 Biosecurity revenue of $8 million with gross profit margin of 15% is reflective of the early stages of transitioning to a more recurring business modelFourth quarter 2023 Loss from operations of $(178) million (inclusive of stock-based compensation expense of $44 million), compared to Loss from operations of $(231) million in the comparable prior year period (inclusive of stock-based compensation expense of $111 million). Just under half of the stock-based compensation expense relates to the continued GAAP accounting for the modification of restricted stock units issued prior to Ginkgo becoming a public company, as disclosed in our annual report on Form 10-K filed with the SEC on March 13, 2023, and which we expect to continue to ramp down significantly in the coming quarters.Fourth quarter 2023 Adjusted EBITDA of $(96) million, down from $(76) million in the comparable prior year period driven by the decline in Total revenue partially offset by a decline in operating expensesCash and cash equivalents balance as of the end of the fourth quarter of $944 million puts Ginkgo in a strong financial position to pursue its strategic objectives

Full Year 2023 Financial Highlights

Full year 2023 Total revenue of $251 million, down from $478 million in the prior year, a decrease of 47% as Biosecurity revenue transitioned from K-12 testing to a more recurring business modelFull year 2023 Cell Engineering revenue of $144 million remained stable over the prior year, representing 31% growth in services revenue offset by a decrease in downstream value share from equity milestonesFull year 2023 Biosecurity revenue of $108 million, down from $334 million in the prior year, a decrease of 68%, with full year 2023 Biosecurity gross profit margin of 50%Full year 2023 Loss from operations of $(864) million (inclusive of stock-based compensation expense of $235 million), compared to $(2.2) billion (inclusive of stock-based compensation expense of $1.9 billion) in the prior yearFull year 2023 Adjusted EBITDA of $(355) million, down from $(173) million in the prior year

Full Year 2024 Guidance

Ginkgo expects to add 100-120 new Cell Programs to the Cell Engineering platform in 2024Ginkgo expects Total revenue of $215–$235 million in 2024Ginkgo expects Cell Engineering services revenue of $165-185 million in 2024 driven by expected growth in biopharma and government programs. This guidance excludes the impact of any potential downstream value share revenue.Ginkgo expects Biosecurity revenue in 2024 of at least $50 million, representing approximate current contracted backlog, with potential upside from additional opportunities in the pipeline

Conference Call Details
Ginkgo will host a videoconference today, Thursday, February 29, 2024, beginning at 5:30 p.m. ET. The presentation will include an overview of the fourth quarter and full year financial performance, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo’s Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:
+1 646 876 9923 (New York)
+1 301 715 8592 (Washington DC)
+1 312 626 6799 (Chicago)
+1 669 900 6833 (San Jose)
+1 253 215 8782 (Tacoma)
+1 346 248 7799 (Houston)
+1 408 638 0968 (San Jose)

Webinar ID: 928 9136 7332

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our web site at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our balance sheet and cash runway, acquisitions, current expectations, operations and anticipated results of operations, both business and financial, including opportunities for increased operational efficiency, our manufacturing capabilities, potential customer success, including successful application of our offerings by our customers, the capabilities and potential operational and financial success of our acquisitions, partnerships and collaborations, and expected timing thereof, expectations with regard to revenue, the nature of such revenue and any related downstream value share associated with such revenue, funding that is contingent upon Ginkgo’s achievement of milestones, expenses, including our stock-based compensation expenses, our full year 2024 outlook, the future security and commercial applications of the BIOINT industry, the expansion, timing and potential capabilities of our bioradar network and the national biodefense strategy, plans to develop and deploy AI tools for biology and biosecurity for both internal use and external release, including the expected timing thereof, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”), and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. 

Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo’s financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
investors@ginkgobioworks.com 

MEDIA CONTACT:
press@ginkgobioworks.com 

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except per share data, unaudited)

As of December 31,

2023

2022

Assets

Current assets:

Cash and cash equivalents

$       944,073

$    1,315,792

Accounts receivable, net

17,157

80,907

Accounts receivable – related parties

742

1,558

Prepaid expenses and other current assets

39,777

51,822

Total current assets

1,001,749

1,450,079

Property, plant and equipment, net

188,193

314,773

Operating lease right-of-use assets

206,801

400,762

Investments

78,565

112,188

Equity method investments

—

1,543

Intangible assets, net

82,741

111,041

Goodwill

49,238

60,210

Other non-current assets

58,055

88,725

Total assets

$    1,665,342

$    2,539,321

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$           9,323

$         10,451

Deferred revenue

44,486

47,817

Accrued expenses and other current liabilities

110,051

114,694

Total current liabilities

163,860

172,962

Non-current liabilities:

Deferred revenue, net of current portion

158,062

174,767

Operating lease liabilities, non-current

221,835

413,256

Warrant liabilities

5,700

10,868

Other non-current liabilities

18,733

31,191

Total liabilities

568,190

803,044

Stockholders’ equity:

Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued

—

—

Common stock, $0.0001 par value

199

190

Additional paid-in capital

6,385,997

6,136,378

Accumulated deficit

(5,290,528)

(4,397,659)

Accumulated other comprehensive income (loss)

1,484

(2,632)

Total stockholders’ equity

1,097,152

1,736,277

Total liabilities and stockholders’ equity

$    1,665,342

$    2,539,321

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share data, unaudited)

Three Months Ended December 31,

Year Ended December 31,

2023

2022

2023

2022

Cell Engineering revenue

$          26,976

$          53,257

$         143,531

$         143,666

Biosecurity revenue:

Product

—

12,431

28,949

35,455

Service

7,779

32,597

78,975

298,585

Total revenue

34,755

98,285

251,455

477,706

Costs and operating expenses:

Cost of Biosecurity product revenue

—

7,447

7,481

20,646

Cost of Biosecurity service revenue

6,611

22,771

46,524

183,570

Research and development

117,038

177,548

580,621

1,052,643

General and administrative

89,223

121,383

385,025

1,429,799

Impairment of lease assets

—

—

96,210

—

Total operating expenses

212,872

329,149

1,115,861

2,686,658

Loss from operations

(178,117)

(230,864)

(864,406)

(2,208,952)

Other income (expense):

Interest income

13,303

11,441

57,217

20,262

Interest expense

(93)

(106)

(93)

(106)

Loss on equity method investments

(1,119)

10,003

(2,635)

(43,761)

Loss on investments

(10,012)

(13,354)

(54,827)

(53,335)

Change in fair value of warrant liabilities

6,555

28,871

5,168

124,970

(Loss) gain on deconsolidation of subsidiaries

(42,502)

—

(42,502)

31,889

Other income (expense), net

93

6,161

9,138

7,634

Total other income (expense), net

(33,775)

43,016

(28,534)

87,553

Loss before income taxes

(211,892)

(187,848)

(892,940)

(2,121,399)

Income tax benefit

(198)

(14,770)

(71)

(15,027)

Net loss

(211,694)

(173,078)

(892,869)

(2,106,372)

Loss attributable to non-controlling interest

—

2,390

—

(1,443)

Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders

$      (211,694)

$      (175,468)

$       (892,869)

$   (2,104,929)

Net loss per share attributable to Ginkgo Bioworks Holdings, Inc.

common stockholders:

Basic

$            (0.11)

$            (0.09)

$             (0.46)

$             (1.25)

Diluted

$            (0.11)

$            (0.10)

$             (0.46)

$             (1.25)

Weighted average common shares outstanding:

Basic

1,977,708

1,854,952

1,944,420

1,679,061

Diluted

1,978,843

1,856,610

1,944,420

1,679,839

Comprehensive loss:

Net loss

$      (211,694)

$      (173,078)

$       (892,869)

$   (2,106,372)

Other comprehensive loss:

Foreign currency translation adjustment

4,383

5,278

4,116

(917)

Total other comprehensive gain (loss)

4,383

5,278

4,116

(917)

Comprehensive loss

$      (207,311)

$      (167,800)

$       (888,753)

$   (2,107,289)

(1)

R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and related earnout shares. Total stock-based compensation expense, inclusive of employer payroll taxes, was allocated as follows (in thousands):

 

Three Months Ended December 31,

Year Ended December 31,

(in thousands)

2023

2022

2023

2022

Research and development

$         26,775

$         68,171

$        148,861

$          738,821

General and administrative

16,809

43,059

86,047

1,202,099

Total

$         43,584

$       111,230

$        234,908

$       1,940,920

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

Year Ended December 31,

2023

2022

Cash flows from operating activities:

Net loss

$       (892,869)

$    (2,106,372)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

70,507

42,552

Stock-based compensation

229,884

1,930,641

Non-cash customer consideration

(1,373)

(34,263)

Loss on equity method investments

2,635

43,761

Loss on investments

54,827

53,335

Change in fair value of notes receivable

2,416

(3,757)

Change in fair value of warrant liabilities

(5,168)

(124,970)

Change in fair value of contingent consideration liability

9,168

(1,262)

Loss (gain) on deconsolidation of subsidiaries

42,502

(31,889)

Impairment of long-lived assets

121,404

—

Deferred income tax benefit

(801)

(14,609)

Loss on disposal of equipment

842

3,091

Non-cash lease expense

28,313

19,082

Non-cash in-process research and development

9,182

1,162

Amortization of finance lease right-of-use assets

1,047

1,871

Non-cash severance and retention bonus expense associated with an acquisition

—

6,152

Other non-cash activity

2,147

283

Changes in operating assets and liabilities:

Accounts receivable

50,068

55,024

Prepaid expenses and other current assets

10,473

(8,523)

Operating lease right-of-use assets

9,275

13,233

Other non-current assets

2,570

921

Accounts payable

(1,183)

(10,844)

Accrued expenses and other current liabilities

16,899

(39,639)

Deferred revenue, current and non-current

(35,917)

(36,417)

Operating lease liabilities, current and non-current

(22,800)

(10,792)

Other non-current liabilities

452

31

Net cash used in operating activities

(295,500)

(252,198)

Cash flows from investing activities:

Purchases of property and equipment

(40,801)

(52,271)

Deconsolidation of subsidiaries – cash

(42,980)

(55,721)

Business acquisitions, net of cash acquired

—

82,367

Asset acquisitions, net of cash acquired

—

(7,639)

Purchases of notes receivable

(350)

(40,000)

Proceeds from notes receivable

—

10,000

Purchase of investment in equity securities

—

(3,691)

Proceeds from sale of equipment

4,428

—

Other

(990)

(439)

Net cash used in investing activities

(80,693)

(67,394)

Cash flows from financing activities:

Proceeds from exercise of stock options

93

240

Taxes paid related to net share settlement of equity awards

(23)

(981)

Principal payments on finance/capital leases and lease financing obligation

(1,295)

(1,237)

Proceeds from public offering, net of issuance costs

—

99,303

Contingent consideration payment

(1,411)

(521)

Payment of equity issuance costs

(580)

(1,467)

Net cash (used in) provided by financing activities

(3,216)

95,337

Effect of foreign exchange rates on cash and cash equivalents

(588)

908

Net decrease in cash, cash equivalents and restricted cash

(379,997)

(223,347)

Cash and cash equivalents, beginning of period

1,315,792

1,550,004

Restricted cash, beginning of period

53,789

42,924

Cash, cash equivalents and restricted cash, beginning of period

1,369,581

1,592,928

Cash and cash equivalents, end of period

944,073

1,315,792

Restricted cash, end of period

45,511

53,789

Cash, cash equivalents and restricted cash, end of period

$         989,584

$      1,369,581

 

Ginkgo Bioworks Holdings, Inc.

Selected Non-GAAP Financial Measures

(in thousands, unaudited)

Three Months Ended December 31,

Year Ended December 31,

(in thousands)

2023

2022

2023

2022

Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders

$      (211,694)

$      (175,468)

$       (892,869)

$    (2,104,929)

Interest income

(13,226)

(11,412)

(57,217)

(20,262)

Interest expense

15

77

93

106

Income tax benefit

(198)

(14,770)

(71)

(15,027)

Depreciation and amortization

12,837

15,667

70,507

42,552

EBITDA

(212,266)

(185,906)

(879,557)

(2,097,560)

Stock-based compensation (1)

43,584

111,230

234,908

1,940,920

Impairment of long-lived assets (2)

—

—

121,404

—

Merger and acquisition related expenses (3)

23,663

26,045

70,771

46,229

Loss on investments

10,012

13,354

54,827

53,335

Loss (gain) on deconsolidation of subsidiaries

42,502

—

42,502

(31,889)

Loss on equity method investments (4)

1,119

(7,612)

2,635

45,315

Change in fair value of warrant liabilities

(6,555)

(28,871)

(5,168)

(124,970)

Change in fair value of notes receivable

2,174

(3,924)

2,295

(4,153)

Adjusted EBITDA

$        (95,767)

$        (75,684)

$       (355,383)

$       (172,773)

(1)

For the years ended December 31, 2023 and 2022, includes $5.0 million and $10.3 million, respectively, in related employer payroll taxes.

(2)

For the year ended December 31, 2023, includes $25.2 million impairment loss on lab equipment and $96.2 million impairment loss on a right-of-use asset and the related leasehold improvements associated with an exited Zymergen leased facility.

(3)

Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, (iv) acquired intangible assets expensed as in-process research and development, and (v) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.

(4)

Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests.

 

Ginkgo Bioworks Holdings, Inc.

Segment Information

(in thousands, unaudited)

Three Months Ended December 31,

Year Ended December 31,

2023

2022

2023

2022

Revenue:

Cell Engineering

$            26,976

$         53,257

$       143,531

$       143,666

Biosecurity

7,779

45,028

107,924

334,040

Total revenue

34,755

98,285

251,455

477,706

Segment cost of revenue:

Biosecurity

6,611

30,218

54,005

204,216

Segment research and development expense:

Cell Engineering

77,999

95,408

353,493

273,356

Biosecurity

191

590

1,599

1,937

Total segment research and development expense

78,190

95,998

355,092

275,293

Segment general and administrative expense:

Cell Engineering

60,047

63,686

215,263

168,586

Biosecurity

12,652

13,670

55,514

56,353

Total segment general and administrative expense

72,699

77,356

270,777

224,939

Segment operating (loss) income:

Cell Engineering

(111,070)

(105,837)

(425,225)

(298,276)

Biosecurity

(11,675)

550

(3,194)

71,534

Total segment operating loss

(122,745)

(105,287)

(428,419)

(226,742)

Operating expenses not allocated to segments:

Stock-based compensation (1)

43,584

111,230

234,908

1,940,920

Impairment of long-lived assets

—

—

121,404

—

Depreciation and amortization

12,837

15,667

70,507

42,552

Change in fair value of contingent consideration liability

(1,049)

(1,320)

9,168

(1,262)

Loss from operations

$        (178,117)

$     (230,864)

$     (864,406)

$  (2,208,952)

(1)

Includes $5.0 million and $10.3 million in related employer payroll taxes for the years ended December 31, 2023 and 2022, respectively.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2023-financial-results-302076484.html

SOURCE Ginkgo Bioworks

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

FOMO Pay Among First Design Partners in Circle Payments Network, Powering Real-Time Cross-Border Stablecoin Transactions

Published

12 minutes ago

on

April 25, 2025

By

SINGAPORE, April 25, 2025 /PRNewswire/ — FOMO Pay, a leading major payment institution headquartered in Singapore, has been invited to join the newly launched Circle Payments Network (CPN) as one of its first design partners globally. As a member of the CPN, FOMO Pay will play a key role in advancing compliant, efficient, and real-time cross-border payments powered by regulated stablecoins.

Introduced by Circle, a global financial technology company and stablecoin market leader, the Circle Payments Network enables financial institutions and businesses to settle cross-border transactions in stablecoins with near-instant settlement. As one of the founding network partners, FOMO Pay will play a key role in the real-time settlement of cross-border payments using stablecoins, helping businesses and institutions transact seamlessly between fiat and stablecoins.

“As a member of the Circle Payments Network, FOMO Pay is proud to work alongside Circle to advance the adoption of compliant and fast stablecoin payments,” said Louis Liu, Founder and CEO of FOMO Pay. “In addition to FOMO Pay’s established local payment and banking rails across Southeast Asia, the Greater Bay Area, the Middle East and North Africa, Europe, and the United States, this collaboration with Circle positions us to support the growing regional demand for stablecoin-powered payments. “

By supporting real-time stablecoin transactions, FOMO Pay continues to help merchants, corporates, and financial institutions streamline cross-border transactions and accelerate trade settlement across markets.

About FOMO Pay

Founded in 2015, FOMO Pay is a Major Payment Institution licensed in Singapore, Hong Kong and the United Arab Emirates (UAE). The firm has become a leading one-stop digital payment, digital banking, and digital asset solution provider. It is currently building Asia’s fully licensed financial platform, helping institutions and businesses connect between traditional and next-generation financial services. The firm offers its three flagship products:

FOMO Payment – One-stop digital payment solution for merchants, corporates and financial institutionsFOMO iBank – Facilitate businesses’ everyday requirements for transactional banking needsFOMO Treasury – One-stop digital asset services provider bridging Web 2.0 & Web 3.0

Visit www.fomopay.com for more information.

 

View original content:https://www.prnewswire.com/apac/news-releases/fomo-pay-among-first-design-partners-in-circle-payments-network-powering-real-time-cross-border-stablecoin-transactions-302437436.html

SOURCE FOMO Pay

Continue Reading

Technology

OverActive Media Reports Record Q4 and FY 2024 Results: Q4 Revenue Up 134%, FY Revenue Up 72%, $311,000 of Comprehensive Income

Published

12 minutes ago

on

April 25, 2025

By

Streamlined Operations and Solid Balance Sheet Position the Company for Sustainable Growth in 2025

TORONTO, April 24, 2025 /CNW/ – OverActive Media Corp. (“OverActive” or the “Company”) (TSXV: OAM) (OTC: OAMCF), a global esports and entertainment company for today’s generation of fans, released its results for the three and twelve-month periods ended December 31, 2024.

Financial Results Summary for Q4 and FY 2024

$CAD (000’s)

Three
months
ended
December 31, 
2024

Three
months
ended
December 31, 
2023

Variance 
(%)

Twelve
months
ended
December 31, 
2024

Twelve
months
ended
December 31, 
2023

Variance 
(%)

Revenue

$9,852

$4,212

134 %

$27,008

$15,704

72 %

Gross Profit

$5,323

$3,361

58 %

$16,811

$10,384

62 %

Gross Margin

54 %

80 %

-32 %

62 %

66 %

-6 %

Operating Expenses     

$6,646

$4,306

54 %

$23,394

$17,096

37 %

Adjusted EBITDAi

($554)

($699)

21 %

($3,593)

($6,207)

42 %

Comprehensive
Income (Loss)

($1,301)

($768)

-69 %

$311

($12,239)

103 %

Net Working Capital

$6,562

$8,602

-24 %

$6,562

$8,602

-24 %

Cash & Equivalents

$6,849

$13,933

-51 %

$6,849

$13,933

-51 %

(i) Adjusted EBITDA is a non-IFRS measures. Refer to “Non-IFRS Measures” at the end of this press release.

“2024 was a year of real progress for OverActive Media,” said Adam Adamou, CEO and Co-Founder of OverActive Media. “We completed two major acquisitions, expanded into new games and regions, and grew our revenue by 72 percent. Managing that kind of growth while integrating teams and operating across multiple markets required focus, coordination, and an incredible effort from our entire organization.”

Adamou continued, “We’re proud of what we’ve built, but we know we’re not finished. Our priority in 2025 is to continue growing responsibly, improving margins, staying disciplined, and making sure that every step we take adds lasting value. We’re entering this next chapter with momentum, a strong foundation, and a clear plan to keep building a great business in a growing global industry.”

Q4 2024 Financial Highlights

Revenue totaled $9.9 million, up 134% year-over-year, compared to $4.2 million in the same period in 2023. The increase was primarily driven by higher league share, expanded partnerships, and influencer agency revenue from the KOI and Riders acquisitions.Gross profit increased by $1.9 million to $5.3 million with a gross margin of 54%, compared to $3.4 million and 80% in 2023. Margins were impacted by the newly integrated influencer business.Operating costs increased by 54%, totaling $6.6 million, compared to $4.3 million in the same period in 2023. The increase was due to additional headcount, content production, and agency infrastructure tied to strategic expansion.Adjusted EBITDA improved to a loss of $554,000, compared to a loss of $699,000 in Q4 2023, reflecting positive impact of high-margin digital sales and improved operational leverage.Comprehensive loss for the quarter was $1.3 million, compared to a loss of $768,000 in Q4 2023, primarily driven by foreign currency translation losses.Net working capital (current assets less current liabilities) was $6.6 million. Cash and cash equivalents were $6.8 million, reflecting capital deployment into integration and growth. These amounts are net of an additional $782,000 invested in the venue project in Toronto. Total investments in the venue project to date are $2.1 million.

Full Year 2024 Financial Highlights

Revenue reached $27.0 million, up 72%, compared to $15.7 million in FY 2023, driven by acquisitions and growth across team operations, digital merchandise sales (MTX), brand partnerships, influencer business and live events – broadening OverActive’s revenue mix and geographic reach.Gross profit totaled $16.8 million, a 62% increase. Margin declined to 62% from 66%, due to changes in product mix, including lower-margin revenue from the influencer agency and live events.Operating costs were $23.4 million, up 37%, driven by investments in talent, systems, and platform efficiency, along with a $2.3 million one-time restructuring and business development expense tied to acquisitions.Adjusted EBITDA loss improved by 42% to $3.6 million, compared to a loss of $6.2 million in 2023.Comprehensive income of $311,000, compared to a loss of $12.2 million in FY 2023, reflecting a 103% year-over-year improvement, driven by strong revenue growth, disciplined cost management, an $11.5 million gain from the elimination of franchise liabilities, and favorable foreign currency translation.

OverActive Media – Major Accomplishments 2024 To-Date

Financial & Strategic Growth

72% year-over-year revenue growth, reaching a record $27.0 million.Positive comprehensive income of $311,000, a 10% improvement from loss of $12.2 million in 2023.42% improvement in adjusted EBITDA loss, driven by stronger revenue and improved operating efficiency.$11.5 million gain from the elimination of long-term franchise obligations, significantly strengthening the Company’s balance sheet.

Mergers & Acquisitions

Acquired KOI and Movistar Riders, expanding the Company’s footprint across Europe and Latin America and introducing new business lines including influencer agency operations.OverActive was awarded a VALORANT Champions Tour EMEA (VCT EMEA) partnership by Riot Games.

Global Expansion

Entered Latin America via Movistar KOI’s participation in the Free Fire League in Mexico, strengthening the Company’s multiyear partnership with Telefónica and presence in Latin America.Invited into the inaugural Esports World Cup Foundation Partner Program 2024 and for the 2025 season.Announced expansion into China, world’s largest and fastest-growing esports market, with Movistar KOI launching localized content on Weibo and Bilibili.

Competitive Success

MAD Lions KOI qualified for League of Legends World Championships for the sixth consecutive year, reaching 2.5M peak concurrent viewers.Toronto Ultra won CDL Major I, continuing its run as one of the top Call of Duty teams in the world.Toronto Defiant won back-to-back-to-back-to-back North American Championships in the inaugural Overwatch World Championship Series.OverActive Media finished in 11th place globally in the inaugural Esports World Cup.

Live Events & Viewership

Hosted Call of Duty Major III in Toronto from May 16 to May 19, 2024, drawing an average of 116,400 viewers across 30 hours of airtime and totaling 3.5 million hours watch.Hosted the inaugural KOIKON in Madrid on December 6, 2024, drawing over 3,000 in-person attendees and more than 1 million livestream viewers.Hosted CDL Major I in Madrid with 12,000+ fans. This was the first CDL event hosted in Europe in five years and was produced in tandem as a joint Toronto Ultra and Movistar KOI event.Announced that the first ever LEC Roadtrip will be hosted by OverActive Media’s Movistar KOI at the Madrid Arena, with an expected 16,000 fans attending over two days, April 26 and 27.Announced as the host of the 2025 Call of Duty League® Championship Weekend powered by Bell in Ontario from June 26-29, expected to draw over 20,000 fans.

Commercial & Brand Partnerships

Renewed and expanded partnerships with Telefónica, AMD, Bell, SCUF Gaming.Signed new partnerships with Monster Energy, CUPRA, and Blacklyte.Announced LEC naming rights deal with Telefónica, the first of its kind in the LEC.

Sustainability & ESG

Partnered with Ecoembes to support sustainability initiatives and join the United Nations Sports for Climate Action Framework.

Subsequent to the Quarter

On April 19, 2025, Stewart Johnston stepped down from OverActive Media’s Board of Directors following his departure from Bell to pursue another opportunity. The Company extends its gratitude to Mr. Johnston for his valuable service and significant contributions.OverActive Media has retained Red Cloud Securities Inc. to provide market-making services in accordance with TSX Venture Exchange policies. The agreement commenced on April 15, 2025. Red Cloud will receive a monthly fee of $4,500 CAD for its services, which are intended to enhance the liquidity and trading activity of OverActive Media’s common shares. The engagement is open-ended and may be terminated by either party with 30 days’ written notice. No performance-based compensation or securities have been granted in connection with this arrangement.

Conference Call Details

The Company will conduct a conference call on Friday, April 25, 2025, at 9:00 a.m. ET.

To access the call, register at https://emportal.ink/3XSQ1QW or dial 1-888-699-1199 (North America) or 416-945-7677 (International).

A replay will be available until May 2, 2025, at 1-888-660-6345 or 289-819-1450 using entry code 23519#.

A webcast will also be available at https://app.webinar.net/2XjxkN4wv8K and archived for three months.

ABOUT OVERACTIVE MEDIA 

OverActive Media Corp. (TSXV: OAM) (OTC:OAMCF) is headquartered in Toronto, Ontario, with operations in Madrid, Spain and Berlin, Germany, is a premier global esports and entertainment company for today’s generation of fan. OverActive owns team franchises in professional esports leagues, including the Call of Duty League, operating as the Toronto Ultra, the League of Legends EMEA Championship (LEC), operating as Movistar KOI, the VALORANT Champions League (VCT) EMEA, operating as Movistar KOI and other professional esports leagues and competitions.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This press release contains statements which constitute “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking statements”), including statements regarding the plans, intentions, beliefs and current expectations of OverActive with respect to future business activities and operating performance. Forward-looking statements are often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding the anticipated financial and operating results of OverActive in the future.

Investors are cautioned that forward-looking statements are not based on historical facts but instead OverActive management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although OverActive believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the OverActive. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements include the following: the potential impact of OverActive’s qualifying transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws and regulations both locally and in foreign jurisdictions; compliance with extensive government regulation; the risks and uncertainties associated with foreign markets; the ability of the Company to continue to execute on its existing partnerships and business strategy; the ability of the MAD Lions and Call of Duty Leagues to maintain viewership; the successful completion of the Company’s new venue; and other risk factors set out in OverActive’s most recent annual information form and its other filings with Canadian securities regulators, copies of which may be found under OverActive’s profile at www.sedarplus.ca. These forward-looking statements may be affected by risks and uncertainties in the business of OverActive and general market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although OverActive has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. OverActive does not intend and do not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.

NON-IFRS MEASURES

This press release includes references to Adjusted EBITDA. This non-IFRS financial measure is not an earnings or cash flow measure recognized by IFRS and does not have a standardized meaning prescribed by IFRS. Our method of calculating this financial measure may differ from the methods used by other issuers and, accordingly, our definition of this non-IFRS financial measure may not be comparable to similar measures presented by other issuers. Investors are cautioned that non-IFRS financial measures should not be construed as an alternative to net income determined in accordance with IFRS as indicators of our performance or to cash flows from operating activities as measures of liquidity and cash flows.

Adjusted EBITDA is defined by the Company net income or loss before income taxes, finance costs, finance income, depreciation and amortization, decrease in net present value of franchise obligations, foreign exchange gains / loss, assistance payments from Franchise League and government assistance, restructuring and business development costs, impairment charges, and share-based compensation. We believe that Adjusted EBITDA is a useful measure of financial performance because it provides an indication of the Company’s ability to capitalize on growth opportunities in a cost-effective manner, finance its ongoing operations and service its financial obligations. A reconciliation of Adjusted EBITDA to net income/loss may be found in the Company’s Management’s Discussion and Analysis for the three and 12-month periods ended December 31, 2024.

The following tables presents a reconciliation of net loss to adjusted EBITDA for the three and twelve months ended December 31, 2024 and 2023:

Three months ended 
December 31,

Twelve months ended
December 31,

2024

2023

2024

2023

$

$

$

$

Net income (loss) for the period

(868)

(1,349)

(629)

(12,519)

Income tax expense (recovery)

122

(668)

(212)

(520)

Depreciation

550

487

2,238

1,800

Amortization and impairment

325

240

1,069

399

Decrease in net present value of franchise obligations

(1,701)

(1,059)

(11,539)

(1,059)

Finance income

(32)

(32)

(254)

(214)

Finance costs

89

1,208

1,692

5,050

Foreign exchange (gain) loss

(7)

(91)

896

28

Share-based compensation

347

207

715

152

Restructuring and development costs

621

358

2,431

676

  Adjusted EBITDA

(554)

(699)

(3,593)

(6,207)

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Overactive Media Corp.

Continue Reading

Technology

Horizon Robotics and Bosch Intensify Collaboration to Provide Assisted Driving Solutions for Multiple Automakers

Published

12 minutes ago

on

April 25, 2025

By

SHANGHAI, April 24, 2025 /PRNewswire/ — Horizon Robotics (stock code: 9660.HK), a leading provider of smart driving solutions for passenger vehicles, and Bosch, a leading global supplier of automotive technology and services, signed a Memorandum of Understanding (MoU), to intensify their collaboration.

According to the agreement, Bosch will develop its new multi purpose camera based on Horizon Robotics’ Journey 6B, and its Bosch ADAS product family for mid segment using the Journey 6E/M, offering enhanced safety, convenience and comfort for both drivers and passengers. Bosch’s new multi purpose camera and its ADAS product family for mid segment, have been awarded design-wins from multiple OEMs.

At the signing ceremony, in the presence of Mr. Wang Weiliang, President of Bosch Mobility Board China, Mr. Christoph Hartung, President of Bosch Cross-Domain Computing Solutions, and Dr. Yu Kai, Founder and CEO of Horizon Robotics, and Mr. Lyu Peng, Vice President of Horizon Robotics and Head of Strategy, Smart Driving Product Planning & Marketing, Mr. Wu Yongqiao, President of Bosch Cross-Domain Computing Solutions China and Mr. Calvin Xing, Vice President of Horizon Robotics and Vice President of Automotive Business Unit, signed the strategic cooperation MoU.

Journey 6B Powered Bosch New Multi Purpose Camera Secures Projects with Several Global and Chinese OEMs
Developed using Horizon’s Journey 6B processing hardware, Bosch’s new multi purpose camera offers a cost-effective solution to support advanced safety and comfort functions for SAE Level 2 assisted driving. With mass production scheduled for mid-2026, the new multi purpose camera has already secured several design wins with global and Chinese OEMs.

Horizon’s Journey 6B is an optimized solution designed for next-generation ADAS systems, focusing on active safety features and engineered specifically as a standard configuration for the industry. Journey 6B allows partners to develop integrated systems that deliver superior performance, optimized cost efficiency and enhanced safety. 

Bosch ADAS Product Family for Mid Segment Based on Journey 6E/M Secures Projects with Five OEMs
Based on Journey 6E/M processing hardware, the Bosch ADAS product family for mid segment enables high-level ADAS features including urban navigation-based assisted driving, supporting up to 10 routes of urban memory driving and parking, and smooth parking with one move parking assist function. Currently, these platforms have secured contracts with five OEMs, including JeTour, Dongfeng, and BAIC, with the first mass-produced model scheduled for launch in June 2025. Additionally, its first overseas project is planned for mass production in Q1 2026, inaugurating Bosch ADAS product family for mid segment global expansion empowered by Horizon’s Journey 6 series.

As an optimal solution to popularize ADAS, Journey 6E/M has gained recognition in the industry for its high performance and cost efficiency. Over 20 OEMs have selected Journey 6, empowering more than 100 smart vehicle models. With its shipments projected to exceed 1 million units by 2025, Horizon is poised to become the industry’s first ADAS technology firm to surpass the 10-million-unit milestone by 2025.

Mr. Wang Weiliang, President of Bosch Mobility Board China said: “At this pivotal moment for vehicle intelligence, Bosch is fully engaged, partnering openly with industrial value chain companies such as Horizon Robotics. By combining our software and hardware expertise in embedded systems, we’re driving the smart mobility revolution together.”

Mr. Christoph Hartung, President of Bosch Cross-Domain Computing Solutions said: “China has become the world’s fitness center for automotive intelligence. With our deep-rooted expertise in safety technologies, global regulatory compliance experience, and comprehensive service network, Bosch serves as the ideal partner for Chinese OEMs to develop local solutions while also identifying opportunities for global scalability. We look forward to collaborating with outstanding partners like Horizon Robotics to jointly advance the global development of intelligent driving technologies.”

Dr. Yu Kai, Founder and CEO of Horizon Robotics said: “We are honored to collaborate with Bosch, a world leader in mobility solutions with a century-long heritage in the automotive industry. We look forward to leveraging our innovative product technologies in collaboration with Bosch to deliver ADAS solutions that meet market demands globally. By deepening our collaboration on the Journey 6 series with leading OEMs, we aim to bring safe, reliable, and enjoyable assisted driving experiences to drivers and passengers worldwide.”

The collaboration between Horizon Robotics and Bosch leverages the two companies’ combined expertise and competitive strengths to deliver state-of-the-art assisted driving technologies. This collaboration will support OEMs in enhancing consumers’ driving and traveling experiences – making them safer, smarter and more comfortable – while accelerating the global adoption of assisted driving mobility technologies.

About Horizon Robotics
With its mission to make human life safer and better, Horizon Robotics is a leading provider of smart driving solutions for passenger vehicles, empowered by its proprietary software and hardware technologies. Its solutions combine cutting-edge algorithms, purpose-built software and processing hardware, providing the core technologies for smart driving that enhance the safety and experience of drivers and passengers. Horizon Robotics is a key enabler for the smart vehicle transformation and commercialization with its integrated solutions deployed on mass scale.

About Bosch
In China, the Bosch Group manufactures and markets automotive original equipment and aftermarket products, industrial drives and control technology, power tools, household appliances, security and communication systems as well as thermotechnology solutions. Having established a regional presence in China in 1909, Bosch employs more than 56,000 associates (as of December 31, 2024). Bosch in China has generated consolidated sales of CNY 142.8 billion in fiscal 2024.

Additional information is available online at www.bosch.com.cn.

The Bosch Group is a leading global supplier of technology and services. It employs roughly 417,900 associates worldwide (as of December 31, 2024). According to preliminary figures, the company generated sales of 90.5 billion euros in 2024. Its operations are divided into four business sectors: Mobility, Industrial Technology, Consumer Goods, and Energy and Building Technology. With its business activities, the company aims to use technology to help shape universal trends such as automation, electrification, digitalization, connectivity, and an orientation to sustainability. In this context, Bosch’s broad diversification across regions and industries strengthens its innovativeness and robustness. Bosch uses its proven expertise in sensor technology, software, and services to offer customers cross-domain solutions from a single source. It also applies its expertise in connectivity and artificial intelligence in order to develop and manufacture user-friendly, sustainable products. With technology that is “Invented for life,” Bosch wants to help improve quality of life and conserve natural resources. The Bosch Group comprises Robert Bosch GmbH and its roughly 470 subsidiary and regional companies in over 60 countries. Including sales and service partners, Bosch’s global manufacturing, engineering, and sales network covers nearly every country in the world. Bosch’s innovative strength is key to the company’s further development. At 136 locations across the globe, Bosch employs some 86,900 associates in research and development, of which nearly 48,000 are software engineers.

The company was set up in Stuttgart in 1886 by Robert Bosch (1861–1942) as “Workshop for Precision Mechanics and Electrical Engineering.” The special ownership structure of Robert Bosch GmbH guarantees the entrepreneurial freedom of the Bosch Group, making it possible for the company to plan over the long term and to undertake significant upfront investments in the safeguarding of its future. Ninety-four percent of the share capital of Robert Bosch GmbH is held by Robert Bosch Stiftung GmbH, a charitable foundation. The remaining shares are held by Robert Bosch GmbH and by a corporation owned by the Bosch family.

The majority of voting rights are held by Robert Bosch Industrietreuhand KG. It is entrusted with the task of safeguarding the company’s long-term existence and in particular its financial independence – in line with the mission handed down in the will of the company’s founder, Robert Bosch.

Additional information is available online at www.bosch.com, www.iot.bosch.com, www.bosch-press.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/horizon-robotics-and-bosch-intensify-collaboration-to-provide-assisted-driving-solutions-for-multiple-automakers-302438071.html

SOURCE Horizon Robotics

Continue Reading

Trending